Phase II trials of the single agents baker's antifol, diaziquone, and epirubicin in advanced pancreatic cancer. Gastrointestinal Tumor Study Group.
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001388:Aziridines / Q000627:therapeutic use*; D001389:Azirines / Q000627:therapeutic use*; D016227:Benzoquinones; D004317:Doxorubicin / Q000627:therapeutic use*; D004341:Drug Evaluation; D015251:Epirubicin; D006801:Humans; D010190:Pancreatic Neoplasms / Q000188:drug therapy*; D014227:Triazines / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D001388:Aziridines; D001389:Azirines; D016227:Benzoquinones; D014227:Triazines; D015251:Epirubicin; D004317:Doxorubicin; C012071:triazinate; C029108:diaziquone